Predicted protein targets (top 13)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | MAPT | P10636 | 4/20 | 0.47 |
| ▸ | F10 | P00742 | 2/20 | 0.46 |
| ▸ | LMNA | P02545 | 7/20 | 0.44 |
| ▸ | SMN1; SMN2 | Q16637 | 2/20 | 0.43 |
| ▸ | TP53 | P04637 | 1/20 | 0.42 |
| ▸ | POLB | P06746 | 1/20 | 0.42 |
| ▸ | KDM4E | B2RXH2 | 1/20 | 0.41 |
| ▸ | ALOX15 | P16050 | 1/20 | 0.41 |
| ▸ | ALDH1A1 | P00352 | 1/20 | 0.41 |
| ▸ | APOBEC3A | P31941 | 1/20 | 0.41 |
| ▸ | APOBEC3G | Q9HC16 | 1/20 | 0.41 |
| ▸ | KMT2A | Q03164 | 1/20 | 0.41 |
| ▸ | HTT | P42858 | 1/20 | 0.41 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL5640946 | 0.91 | MAPT (0.46) | MAPTLMNASMN1; SMN2TP53POLB | |
| SCHEMBL5640079 | 0.89 | KDM4E (0.47) | MAPTPOLBKDM4EALDH1A1KMT2A | |
| SCHEMBL5641232 | 0.86 | HDAC3 (0.43) | MAPTTP53KDM4EKMT2A | |
| SCHEMBL5640468 | 0.85 | F10 (0.48) | MAPTF10LMNASMN1; SMN2TP53 | |
| SCHEMBL5639678 | 0.85 | LMNA (0.41) | MAPTF10LMNATP53POLB | |
| SCHEMBL4586509 | 0.84 | MAPT (0.51) | MAPTF10LMNATP53POLB | |
| SCHEMBL4588026 | 0.83 | MAPT (0.46) | MAPTLMNASMN1; SMN2TP53POLB | |
| SCHEMBL5637894 | 0.83 | LMNA (0.39) | MAPTF10LMNATP53POLB | |
| SCHEMBL5642131 | 0.82 | F10 (0.46) | MAPTF10LMNASMN1; SMN2TP53 | |
| SCHEMBL5641828 | 0.81 | TPSAB1 (0.44) | F10KDM4E |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 2 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-7199149-B2 | Monocyclic and bicyclic lactams as factor Xa inhibitors | BRISTOL MYERS SQUIBB COMPANY (US) | 2007-04-03 | — | — | US | disclosed |
| US-20050107361-A1 | Monocyclic and bicyclic lactams as factor Xa inhibitors | BRISTOL-MYERS SQUIBB COMANY | 2005-05-19 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20050107361-A1 | Monocyclic and bicyclic lactams as factor Xa inhibitors | F2, F12, SPINT2 | MAPT 4614/4885F10 18/4885LMNA 774/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.